Unable to continue due to low enrollment and lack of resources.

The purpose of this study is to evaluate the effectiveness of providing patient medication education about Eliquis and Xarelto through an Amazon Alexa based voice recording.

Anticoagulants are considered high-risk medications due to the risk of major bleeding. The Federal Drug and Food Administration (FDA) MedWatch reporting system found that anticoagulants had the most adverse drug event (ADE) reports in 2011. Anticoagulants have also been reported as one of the leading drug classes contributing to emergency department visits3. Given the potential for serious adverse events, providing effective education to increase patient knowledge and awareness of those risks are essential. Incorporating technology into health care is becoming increasingly popular and has been shown to be effective for patient education. One reason is that technology can consistently provide complete patient education and is not subject to educator variability in providing this education.

Inclusion Criteria (Patients):

• 18 years of age or older
• Have been prescribed either apixaban or rivaroxaban during their inpatient stay
• Consent to participating in the study

Inclusion Criteria (Nurses):

• Providing direct patient care in select general medicine and orthopedic surgical units
• Consent to participating in the study

Exclusion Criteria:

• Patients will be excluded if they have documented altered mental status, do not speak English, or are being prescribed rivaroxaban or apixaban on discharge only.
• Nurses will be excluded if not providing direct patient care in select general medicine and orthopedic surgical units
• Nurses declining participation